C12N 2740/16211
Concerning hiv gagpol
Official title: concerning HIV gagpol
C12N2740/16211 (Concerning hiv gagpol) appears on 956 US grants and 1,016 published applications in this corpus.
Search patents in C12N- Granted patents
- 956
- Published applications
- 1,016
- Assignees
- 564
- Inventors
- 1,855
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 5 | 0 |
| 1990 | 0 | 0 |
| 1991 | 11 | 0 |
| 1992 | 17 | 0 |
| 1993 | 13 | 0 |
| 1994 | 14 | 0 |
| 1995 | 12 | 0 |
| 1996 | 26 | 0 |
| 1997 | 36 | 0 |
| 1998 | 75 | 0 |
| 1999 | 41 | 0 |
| 2000 | 41 | 0 |
| 2001 | 38 | 6 |
| 2002 | 35 | 46 |
| 2003 | 41 | 87 |
| 2004 | 22 | 70 |
| 2005 | 13 | 69 |
| 2006 | 26 | 53 |
| 2007 | 21 | 60 |
| 2008 | 29 | 49 |
| 2009 | 42 | 52 |
| 2010 | 32 | 54 |
| 2011 | 28 | 43 |
| 2012 | 33 | 53 |
| 2013 | 21 | 27 |
| 2014 | 30 | 29 |
| 2015 | 31 | 32 |
| 2016 | 26 | 41 |
| 2017 | 35 | 36 |
| 2018 | 25 | 34 |
| 2019 | 27 | 34 |
| 2020 | 20 | 18 |
| 2021 | 21 | 30 |
| 2022 | 23 | 35 |
| 2023 | 10 | 17 |
| 2024 | 15 | 13 |
| 2025 | 6 | 17 |
| 2026 | 11 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods and compositions for inducing an immune response using conserved element constructs18 Aug 2026US 12,709,635 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- HIV immunotherapy with no pre-immunization step18 Aug 2026US 12,709,753 B2American Gene Technologies International Inc.
- Infectious disease antigens and vaccines5 May 2026US 12,616,746 B2Seattle Project Corp.
- Persistent memory T-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways24 Mar 2026US 12,582,709 B2The Regents of the University of California
- Targeting moDC to enhance vaccine efficacy on mucosal surface10 Mar 2026US 12,569,557 B2University of Florida Research Foundation, Inc.
- Recombinant enzyme for the accurate insertion of dna sequences in eukaryotic cells1 Oct 2026US 2026/0297624 A1Rensselaer Polytechnic Institute
- Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases6 Aug 2026US 2026/0224687 A1Centre National De La Recherche Scientifique
- Directed evolution of engineered virus-like particles (evlps)23 Jul 2026US 2026/0209747 A1President and Fellows of Harvard College
- Compositions and Methods for Targeted Delivery of CRISPR-CAS Effector Polypeptides and Transgenes28 May 2026US 2026/0146247 A1The Regents of the University of California
- Highly networked immunogen composition14 May 2026US 2026/0130984 A1Massachusetts Eye and Ear Infirmary
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies319US 5,558,864 AMerck Patent GmbH · 1996
- Expression using fused genes providing for protein product297US 4,751,180 AChiron Corporation · 1988
- Genetic immunization277US 5,593,972 AThe Trustees of the University of Pennsylvania · 1997
- Recombinant negative strand RNA virus expression-systems218US 5,166,057 AMount Sinai School of Medicine of the City University of New York · 1992